spacer
home > ebr > winter 2002 > determination of absorptivity constants for biopharmaceutical protein products by amino acid analysis
PUBLICATIONS
European Biopharmaceutical Review

Determination of Absorptivity Constants for Biopharmaceutical Protein Products by Amino Acid Analysis

Early in the development of any pharmaceutical product the absorptivity (as) or extinction coefficient (e) of the molecule is determined. Determination of an absorptivity constant for a small organic molecule is often a minor undertaking. The purified and dried molecule is quantitated by gravimetric means, followed by dissolution in an appropriate buffer or solvent and simple ultraviolet/visible light (UV/VIS) spectrophotometric analysis at its l maximum.

For protein-based biopharmaceuticals, however, this is not as easily accomplished. The limiting step is quantitation of the protein, which often contains contaminating proteins, bound salts, metals and excessive amounts of bound water. Quantitation of purified proteins for determination of absorptivity constants in a defined solution has been accomplished in the past by gravimetric, Kjeldahl and colorimetric techniques (1, 2) and by amino acid analysis. Statistically derived approaches for prediction of the absorptivity constants of proteins are also available.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By John C Anders, K Chad Bastian and Glenn E Petrie, Research Associates at AAI International John C Anders received his PhD in Biochemistry and Molecular Biology from the University of Florida in 1990. He completed his postdoctoral work in the Department of Immunology at the Walter Reed Army Institute of Research, Washington DC on development of a malaria vaccine. Subsequent military service at the Medical Research Institute of Chemical Defense focused on bringing biotechnological innovations to the treatment and amelioration of the toxic effects of various chemical warfare agents.
Dr Anders now serves as a Senior Research Associate in the Biotechnology Laboratory of AAI International. His current work focuses on various aspects of protein chemistry upon analysis of biopharmaceuticals in a cGMP laboratory environment.

K Chad Bastian received his PhD in Civil Engineering from Purdue University in 1996 and completed a postdoctoral appointment with the US Geological Survey through the University of Kansas Center for Research, Inc.

Dr Bastian is currently employed by AAI International focusing on applications of HPLC/MS and tandem mass spectrometry to pharmaceutical and biopharmaceutical analysis in a GMP environment.

Glenn Petrie received his PhD in Biochemistry from the University of Illinois in September 1983. He began his career at Allied Signal, Research & Technology, where he designed, staffed and managed a $1.5 million speciality analytical laboratory to support a diverse corporate research laboratory.

He is currently employed in the Analytical Division of AAI International, where he provides technical supervision to a staff of PhD, MS and BS scientists. He works closely with clients to define and manage their method development and validation projects.



spacer
John C Anders
spacer
spacer
spacer
K Chad Bastian
spacer
spacer
spacer
Glenn E Petrie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement